The content on this site is intended for healthcare professionals only
Dr Alexander Drilon speak to ecancer about results from the phase I/II ARROS-1 trial evaluating zidesamtinib in patients with ROS1-positive advanced non-small cell lung cancer (NSCLC) who had not previously received tyrosine kinase inhibitor (TKI) therapy.
He reports that zidesamtinib demonstrated promising antitumour activity, achieving an objective response rate of 93%, with 86% of responses ongoing at 12 months.
Dr Drilon highlights particularly encouraging intracranial activity, with a 100% response rate among 10 evaluable patients with measurable brain metastases, including a 70% complete response rate.
He also reports a manageable safety profile, with low rates of dose reductions and treatment discontinuations.
These findings support further investigation of zidesamtinib as an earlier-line treatment option for patients with ROS1-positive advanced NSCLC.
Subcutaneous tarlatamab shows promising safety and activity in previously treated extensive-stage SCLC
Cemiplimab shows strong survival benefit in KRAS G12C positive advanced NSCLC
Amivantamab plus chemotherapy extends overall survival in EGFR exon 20 insertion NSCLC
Triplet regimen of amivantamab, lazertinib, and pemetrexed showed robust efficacy in advanced EGFR-mNSCLC
JS207 plus chemotherapy enables surgery and deep pathological responses in unresectable NSCLC
Lorlatinib delivers 7-year progression-free survival and durable brain control in ALK+ NSCLC
Is radiotherapy a back up plan after neoadjuvant chemo-immunotherapy in perioperative lung cancer management?
Perioperative anti–PD-L1 therapy improves event-free survival in resectable NSCLC with ctDNA-based risk stratification
Durvalumab plus chemotherapy improves survival in extensive-stage small cell lung cancer regardless of tumour laterality
